Tesofensine

Most Common Uses

Tesofensine is primarily explored for its potential in treating obesity. Clinical studies have shown it promotes significant weight loss by suppressing appetite and increasing metabolism through its action as a serotonin-noradrenaline-dopamine reuptake inhibitor. It has been investigated for use in managing conditions like type 2 diabetes and metabolic syndrome, where weight reduction can improve health outcomes. Additionally, researchers have examined its effects on neurodegenerative disorders, such as Parkinson’s and Alzheimer’s disease, due to its influence on dopamine levels, which may support cognitive function and motor control. While not yet widely approved for clinical use, ongoing trials continue to evaluate its safety and efficacy for these applications.

Mechanism of Action

Tesofensine functions as a SNDRI, enhancing the levels of these neurotransmitters in the brain. It blocks the reuptake transporters for serotonin, noradrenaline, and dopamine, increasing their availability in synaptic clefts. This action influences appetite regulation, energy expenditure, and mood. By elevating dopamine levels, Tesofensine may also support cognitive and motor functions, which initially sparked interest in its use for neurodegenerative disorders. Its effect on noradrenaline contributes to heightened metabolism, while serotonin modulation helps suppress appetite, making it a candidate for obesity treatment. The combined neurotransmitter effects create a multifaceted approach to weight management and potential neurological benefits.

Structure and Pharmacology

Tesofensine, chemically known as (1R,2R,3S)-3-(3,4-dichlorophenyl)-2-(ethoxymethyl)-8-methyl-8-azabicyclo[3.2.1]octane, is a small molecule with a molecular formula of C17H23Cl2NO and a molecular weight of approximately 328.3 g/mol in its base form. Its structure features a tropane backbone, similar to cocaine, but with distinct modifications, including an ethoxymethyl group and a dichlorophenyl ring, which contribute to its unique pharmacological profile. Typically administered as Tesofensine citrate, it has a molecular weight of about 520.4 g/mol due to the citrate salt.

Pharmacologically, Tesofensine acts as a triple reuptake inhibitor, targeting serotonin, noradrenaline, and dopamine transporters in the brain. This inhibition increases the availability of these neurotransmitters in synaptic clefts, influencing appetite suppression, energy expenditure, and mood regulation. The compound exhibits high potency, with a long half-life of approximately 9 days in humans, allowing for sustained effects. Its primary metabolite, NS2360, has an even longer half-life of about 16 days, contributing to prolonged activity. Tesofensine’s ability to elevate dopamine levels supports its exploration for neurodegenerative disorders, while its noradrenaline and serotonin effects drive its potential in obesity management. Clinical studies indicate good oral bioavailability, with peak plasma concentrations reached within hours, making it suitable for once-daily dosing.

Tesofensine Dosage

Tesofensine has been studied primarily in clinical trials for obesity management, with dosages typically administered orally once daily. Research indicates effective doses range from 250mcg to 500mcg per day. The 0.5 mg dose often balances efficacy and tolerability, promoting significant weight loss while minimizing side effects. Higher doses, such as 1.0 mg, have shown greater weight reduction but may increase the likelihood of adverse effects like an increase in heart rate or insomnia. Lower doses, around 0.25 mg, remain effective for some patients with fewer side effects. Dosing in trials for neurodegenerative disorders, such as Parkinson’s or Alzheimer’s disease, has generally followed similar ranges, though specific protocols vary. As Tesofensine is not widely approved, dosing recommendations depend on ongoing research and clinical guidance.

Warnings and Cautions

Tesofensine carries potential risks that require careful consideration. Clinical trials have reported side effects such as increased heart rate, elevated blood pressure, and insomnia, particularly at higher doses like 1.0 mg daily. These cardiovascular effects may pose concerns for people with pre-existing heart conditions or hypertension, necessitating medical supervision. Gastrointestinal issues, including nausea and constipation, have also been observed, alongside potential mood changes such as anxiety or irritability due to its impact on neurotransmitter levels. Long-term use raises concerns about addiction or tolerance, given its effects on dopamine pathways, although data are still limited.

Tesofensine is not recommended for pregnant or breastfeeding women due to insufficient safety studies. Interactions with other medications, especially monoamine oxidase inhibitors or other antidepressants, may amplify risks of serotonin syndrome or other adverse reactions. Patients with a history of psychiatric disorders or seizures should exercise caution, as the inhibitor’s effects on the central nervous system are not fully characterized. Ongoing research continues to evaluate its safety profile, and use should occur under strict clinical guidance.

Research & Clinical Trials

Tesofensine for Weight Loss in Obese Patients

The study concluded that tesofensine, especially at the 0.5 mg dose, significantly reduces body weight in obese patients, producing about twice the weight loss compared to currently approved weight-loss drugs when combined with a diet over 24 weeks. Patients taking tesofensine lost between 4.5% and 10.6% of their body weight depending on the dose, compared to only 2.0% weight loss with diet and placebo. The substance was generally well tolerated, with common side effects including dry mouth, nausea, constipation, diarrhea, and insomnia. While blood pressure was not significantly affected at lower doses, the 0.5 mg dose caused a slight increase in heart rate. Overall, the results suggest tesofensine has promising weight-loss potential, but further larger phase III trials are needed to confirm its efficacy and safety. [1]

Tesofensine, an Antiobesity Inhibitor, Suppresses Hypothalamic GABAergic Neurons

The study concluded that tesofensine is a highly effective anti-obesity inhibitor that works by reducing food intake and promoting weight loss through specific effects on brain circuits that control hunger, especially by inhibiting certain GABAergic neurons in the lateral hypothalamus (LH).

It was shown to be more effective in obese rats than in lean ones, suggesting it may have stronger benefits for those with excess body fat. Tesofensine prolonged weight loss, prevented rebound weight gain (which often follows dieting), and worked well in combination with other drugs like 5-HTP (a serotonin precursor). Importantly, it did not cause negative side effects like taste aversion or stereotypic behaviors often associated with other stimulants such as phentermine. These findings suggest tesofensine could be a promising standalone or add-on therapy for obesity with a unique mechanism that targets specific neurons related to feeding behavior. [2]